This podcast series offers a comprehensive overview of the HIV landscape in the United States, recounting the beginnings of the HIV epidemic and the emergence of drug resistance, exploring current prevention strategies and unmet needs, and examining the evolution of antiretroviral therapy (ART) for both HIV treatment and prevention. This series also highlights the importance and benefits of rapid ART initiation and concludes with a discussion on the benefits of pan-viral screening and integrated care for HIV and hepatitis.

This is an Industry Podcast Sponsored by Gilead Sciences; Not for CME/ CE Credit. The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast series is not intended to be and should not be understood to provide medical advice. Listeners should note that discussions in this podcast series are relevant to the USA only and may not be appropriate for other regions.